Perspectives on glucocorticoid-induced osteoporosis

Bone

Volumn 34, Issue 4, 2004, Pages 593-598

  Canalis, Ernesto ^a,b   Bilezikian, John P ^c   Angeli, Alberto ^d   Giustina, Andrea ^e  

^a SAINT FRANCIS HOSPITAL AND MEDICAL CENTER   (United States)

^b UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^c Columbia University ^*  (United States)

^d UNIVERSITY OF TURIN   (Italy)

^e UNIVERSITY OF BRESCIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CLODRONIC ACID; ESTROGEN; ETIDRONIC ACID; GLUCOCORTICOID; PAMIDRONIC ACID; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PREDNISOLONE; RISEDRONIC ACID; STEROID; VITAMIN D;

BONE DEMINERALIZATION; BONE DENSITY; BONE TURNOVER; CANCELLOUS BONE; CELL ACTIVITY; CHRONIC LUNG DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; DISEASE ACTIVITY; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; DRUG SENSITIVITY; ENTERITIS; ENZYME ACTIVITY; EPIDEMIOLOGICAL DATA; FRACTURE; FRAGILITY FRACTURE; HORMONAL THERAPY; HORMONE ACTION; HUMAN; MYOPATHY; OSSIFICATION; OSTEOLYSIS; PATHOPHYSIOLOGY; PATIENT CARE; POSTMENOPAUSE OSTEOPOROSIS; PRESCRIPTION; PROTEIN FUNCTION; RECIPIENT; REVIEW; RHEUMATIC DISEASE; SECONDARY OSTEOPOROSIS; SIGNAL TRANSDUCTION; VITAMIN SUPPLEMENTATION;

EID: 1642343232     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2003.11.026     Document Type: Article

References (65)

1. Canalis E. Mechanisms of glucocorticoid action in bone: implications to glucocorticoid-induced osteoporosis. J. Clin. Endocrinol. Metab. 81:1996;3441-3447.
2. Hofbauer L.C., Gori F., Riggs B.L., Lacey D.L., Dunstan C.R., Spelsberg T.C.et al. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology. 140:1999;4382-4389.
3. Rubin J., Biskobing D.M., Jadhav L., Fan D., Nanes M.S., Perkins S.et al. Dexamethasone promotes expression of membrane-bound macrophage colony-stimulating factor in murine osteoblast-like cells. Endocrinology. 139:1998;1006-1012.
4. Dempster D.W., Moonga B.S., Stein L.S., Horbert W.R., Antakly T. Glucocorticoids inhibit bone resorption by isolated rat osteoclasts by enhancing apoptosis. J. Endocrinol. 154:1997;397-406.
5. Weinstein R.S., Chen J.R., Powers C.C., Stewart S.A., Landes R.D., Bellido T.et al. Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids. J. Clin. Invest. 109:2002;1041-1048.
6. Hahn T.J., Halstead L.R., Teitelbaum S.L., Hahn B.H. Altered mineral metabolism in glucocorticoid-induced osteopenia. J. Clin. Invest. 64:1979;655-665.
7. Hattersley A.T., Meeran K., Burrin J., Hill P., Shiner R., Ibbertson H.K. The effect of long- and short-term corticosteroids on plasma calcitonin and parathyroid hormone levels. Calcif. Tissue Int. 54:1994;198-202.
8. Urena P, Iida-Klein A, Kong XF, Juppner H, Kronenberg HM, Abou-Samra AB, et al. Regulation of parathyroid hormone (PTH)/PTH-related peptide receptor messenger ribonucleic acid by glucocorticoids and PTH in ROS 17/2.8 and OK cells. 1994;134:451-6.
9. Rubin M.R., Bilezikian J.P. The role of parathyroid hormone in the pathogenesis of glucocorticoid-induced osteoporosis: a re-examination of the evidence. J. Clin. Endocrinol. Metab. 87:2002;4033-4041.
10. Paz-Pacheco E., Fuleihan G.E., LeBoff M.S. Intact parathyroid hormone levels are not elevated in glucocorticoid-treated subjects. J. Bone Miner. Res. 10:1995;1713-1718.
11. Slovik D.M., Neer R.M., Ohman J.L., Lowell F.C., Clark M.B., Segre G.V. et al. Parathyroid hormone and 25-hydroxyvitamin D levels in glucocorticoid-treated patients. Clin. Endocrinol. 12:1980;243-248.
12. Giustina A. Chronic glucocorticoid treatment alters the spontaneous pulsatile parathyroid hormone (PTH) secretory pattern in humans. Proc. of the 83rd Annual Meeting of The Endocrine Society, Denver, CO. 2001;125.
13. Bilezikian JP, Silverberg SJ, Shane E, Parisien M, Dempster DW, Characterization and evaluation of asymptomatic primary hyperparathyroidism. J Bone Miner Res 1991;6(Suppl 2):S85-S89, S121-S124.
14. Silverberg S.J., Shane E., de la Cruz L., Dempster D.W., Feldman F., Seldin D.et al. Skeletal disease in primary hyperparathyroidism. J. Bone Miner. Res. 4:1989;283-291.
15. Laan R.F., Buijs W.C., van Erning L.J., Lemmens J.A., Corstens F.H., Ruijs S.H.et al. Differential effects of glucocorticoids on cortical appendicular and cortical vertebral bone mineral content. Calcif. Tissue Int. 52:1993;5-9.
16. Reid I.R., Evans M.C., Stapleton J. Lateral spine densitometry is a more sensitive indicator of glucocorticoid-induced bone loss. J. Bone Miner. Res. 7:1992;1221-1225.
17. Carbonare L.D., Arlot M.E., Chavassieux P.M., Roux J.P., Portero N.R., Meunier P.J. Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis. J. Bone Miner. Res. 16:2001;97-103.
18. Parisien M., Silverberg S.J., Shane E., de la Cruz L., Lindsay R., Bilezikian J.P.et al. The histomorphometry of bone in primary hyperparathyroidism; preservation of cancellous bone structure. J. Clin. Endocrinol. Metab. 70:1990;930-938.
19. Pereira R.M.R., Delany A.M., Canalis E. Cortisol inhibits the differentiation and apoptosis of osteoblasts in culture. Bone. 28:2001;484-490.
20. Canalis E., Centrella M., Burch M., McCarthy T.L. Insulin-like growth factor I mediates selected anabolic effects of parathyroid hormone in bone cultures. J. Clin. Invest. 83:1989;60-65.
21. Pereira R.C., Delany A.M., Canalis E. Effects of cortisol and bone morphogenetic protein-2 on stromal cell differentiation: correlation with CCAAT-enhancer binding protein expression. Bone. 30:2002;685-691.
22. Weinstein R.S., Jilka R.L., Parfitt A.M., Manolagas S.C. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. J. Clin. Invest. 102:1998;274-282.
23. Bellows C.G., Aubin J.E., Heersche J.N.M. Physiological concentrations of glucocorticoids stimulate formation of bone nodules from isolated rat calvaria cells in vitro. Endocrinology. 212:1987;1985-1992.
24. Ramji D.P., Foka P. CCAAT/enhancer-binding proteins: structure, function and regulation. Biochem. J. 365:2002;561-575.
25. Wu Z., Bucher N.L.R., Farmer S.R. Induction of peroxisome proliferator-activated receptor γ during the conversion of 3T3 fibroblasts into adipocytes is mediated by C/EBPβ, C/EBPδ, and glucocorticoids. Mol. Cell. Biol. 16:1996;4128-4136.
26. Pereira R.M.R., Delany A.M., Durant D., Canalis E. Cortisol regulates the expression of Notch in osteoblasts. J. Cell. Biochem. 85:2002;252-258.
27. Sciaudone M, Gazzerro E, Priest L, Delany AM, Canalis E, Notch 1 impairs osteoblastic cell differentiation. Endocrinology (in press).
28. Weinmaster G. Review: the ins and outs of notch signaling. Mol. Cell. Neurosci. 9:1997;91-102.
29. Mumm J.S., Kopan R. Notch signaling: from the outside in. Dev. Biol. 228:2000;151-165.
30. Dallas D.J., Genever P.G., Patton A.J., Millichip M.I., McKie N., Skerry T.M. Localization of ADAM10 and Notch receptors in bone. Bone. 25:1999;9-15.
31. Axelrod J.D., Matsuno K., Artavanis-Tsakonas S., Perrimon N. Interaction between Wingless and Notch signaling pathways mediated by Dishevelled. Science. 271:1996;1826-1832.
32. Garces C., Ruiz-Hidalgo M.J., Font de Mora J., Park C., Miele L., Goldstein J.et al. Notch-1 controls the expression of fatty acid-activated transcription factors and is required for adipogenesis. J. Biol. Chem. 272:1997;29729-29734.
33. Ross S.E., Hemati N., Longo K.A., Bennett C.N., Lucas P.C., Erickson R.L.et al. Inhibition of adipogenesis by Wnt signaling. Science. 289:2000;950-953.
34. Giustina A., Bussi A.R., Jacobello C., Wehrenberg W.B. Effects of recombinant human growth hormone (GH) on bone and intermediary metabolism in patients receiving chronic glucocorticoid treatment with suppressed endogenous GH response to GH-releasing hormone. J. Clin. Endocrinol. Metab. 80:1995;122-129.
35. Delany A.M., Durant D., Canalis E. Glucocorticoid suppression of IGF I transcription in osteoblasts. Mol. Endocrinol. 15:2001;1781-1789.
36. Diederich S., Quinkler M., Burkhardt P., Grossman C., Bahr V., Oelkers W. 11β hydroxysteroid dehydrogenase isoforms: tissue distribution and implications for clinical medicine. Eur. J. Clin. Invest. 30:2000;21-27.
37. Canalis E., Delany A.M. 11β-Hydroxysteroid dehydrogenase, an amplifier of glucocorticoid action in osteoblasts. J. Bone Miner. Res. 17:2002;987-990.
38. Cooper M.S., Rabbitt E.H., Goddard P.E., Bartlett W.A., Hewison M., Stewart P.M. Autocrine activation of glucocorticoids in osteoblasts increase with age and glucocorticoid exposure. J. Bone Miner. Res. 17:2002;979-986.
39. Riggs B.L., Melton L.J. Evidence for two distinct syndromes of involutional osteoporosis. Am. J. Med. 75:1983;899-901.
40. Cooper M.S., Bujalska I., Rabbitt E., Walker E.A., Bland R., Sheppard M.C.et al. Modulation of 11beta-hydroxysteroid dehydrogenase isozymes by proinflammatory cytokines in osteoblasts: an autocrine switch from glucocorticoid inactivation to activation. J. Bone Miner. Res. 16:2001;1037-1044.
41. Williams L.J., Lyons V., MacLeod I., Rajan V., Darlington G.J., Poli V. et al. C/EBP regulates hepatic transcription of 11beta-hydroxysteroid dehydrogenase type1. A novel mechanism for cross-talk between the C/EBP and glucocorticoid signaling pathways. J. Biol. Chem. 275:2000;30232-30239.
42. Guidelines Writing Group, Royal College of Physicians of London, London NW1 4LE.
43. van Staa T.P., Leufkens H.G.M., Abenhaim L., Begaud B. Use of oral corticosteroids in the United Kingdom. Q. J. Med. 93:2000;105-111.
44. van Staa T.P., Leufkens H.G.M., Abenhaim L., Zhang B., Cooper C. Use of oral corticosteroids and risk of fractures. J. Bone Miner. Res. 15:2000;993-1000.
45. Reid D.M., Hughes R.A., Laan R.F.J.M., Sacco-Gibson N.A., Wenderoth D.H., Adami S.et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. J. Bone Miner. Res. 15:2000;1006-1013.
46. Solomon D.H., Katz J.N., Jacobs J.P., La Tourette A.M., Coblyn J. Management of glucocorticoid-induced osteoporosis in patients with rheumatoid arthritis. Arthritis Rheum. 46:2002;3136-3142.
47. Hooyman J.R., Melton L.J., Nelson A.M., O'Fallon W.N., Riggs B.L. Fractures after rheumatoid arthritis - A population based study. Arthritis Rheum. 27:1984;1353-1361.
48. van Staa T.P., Leufkens H.G., Cooper C. Use of inhaled corticosteroids and risk of fractures. J. Bone Miner. Res. 16:2001;581-588.
49. Bernstein C.N., Blanchard J.F., Leslie W., Wajda A., Yu B.N. The incidence of fracture among patients with inflammatory bowel disease. A population-based cohort study. Ann. Intern. Med. 133:2000;795-799.
50. Sylvester F.A. Bone abnormalities in gastrointestinal and hepatic disease. Rev. Endocr. Metab. Disord. 2:2001;75-80.
51. Haderslev K.V., Tjelleson L., Sorensen H.A., Staun M. Alendronate increases lumbar spine bone mineral density in patients with Crohn's disease. Gastroenterology. 119:2000;866-869.
52. Cohen A., Shane E. Osteoporosis after solid organ and bone marrow transplantation. Osteoporos. Int. 14:2003;617-630.
53. Wong C.A., Walsh L.J., Smith C.J., Wisniewski A.F., Lewis S.A., Hubbard R.et al. Inhaled corticosteroid use and bone-mineral density in patients with asthma. Lancet. 22:2000;1399-1403.
54. Israel E., Banerjee T.R., Fitzmaurice G.M., Kotlov T.V., LaHive K., LeBoff M.S. Effects of inhaled glucocorticoids on bone density in premenopausal women. N. Engl. J. Med. 345:2001;941-947.
55. American College of Rheumatology Ad Hoc Committee on Glucocorticoid- Induced Osteoporosis Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum. 44:2001;1496-1503.
56. Canalis E., Giustina A. Glucocorticoid-induced osteoporosis: summary of a workshop. J. Clin. Endocrinol. Metab. 86:2001;5681-5685.
57. Adachi J.D., Bensen W.G., Brown J., Hanley D., Hodsman A., Josse R.et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N. Engl. J. Med. 337:1997;382-387.
58. Saag K.G., Emkey R., Schnitzer T.J., Brown J.P., Hawkins F., Goemaere S.et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N. Engl. J. Med. 339:1998;292-299.
59. Cohen S.K., Levy R.M., Keller M., Boling E., Emkey R.D., Greenwald M.et al. Risedronate therapy prevents corticosteroid-induced bone loss. A twelve-month, multi-center, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. 42:1999;2309-2318.
60. Boutsen Y., Jamart J., Esselinckx W., Devogelaer J.P. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone. J. Bone Miner. Res. 16:2001;104-112.
61. Lane N.E., Sanchez S., Modin G.W., Genant H.K., Pierini E., Arnaud C.D. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J. Clin. Invest. 102:1998;1627-1633.
62. Franchimont N., Canalis E. Management of glucocorticoid induced osteoporosis in premenopausal women with arthritis. Autoimmun. Rev. 2:2003;224-228.
63. Reichardt H.M., Kaestner K.H., Tuckermann J., Kretz O., Wessely O., Bock Gass P.et al. DNA binding of the glucocorticoid receptor is not essential for survival. Cell. 15:1998;531-541.
64. Paul-Clark M.J., Mancini L., Del Soldato P., Flower R.J., Perretti M. Potent antiarthritic properties of a glucocorticoid derivative, NCX-1015, in an experimental model of arthritis. Proc. Natl. Acad. Sci. U. S. A. 99:2002;1677-1682.
65. Ma K., Mallidis C., Bhasin S., Mahabadi V., Artaza J., Gonzalez-Cadavid N.et al. Glucocorticoid-induced skeletal muscle atrophy is associated with upregulation of myostatin gene expression. Am. J. Physiol. Endocrinol. Metab. 285:2003;E363-E371.